These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 32929408)

  • 21. Synthesis and Characterization of a Positron Emission Tomography Imaging Probe Selectively Targeting the Second Bromodomain of Bromodomain Protein BRD4.
    Bai P; Lan Y; Wang H; Liu Y; Striar R; Yuan G; Afshar S; Zagaroli JS; Tocci DR; Langan AG; Wang C
    Bioconjug Chem; 2021 Aug; 32(8):1711-1718. PubMed ID: 34139120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Binding selectivity of inhibitors toward the first over the second bromodomain of BRD4: theoretical insights from free energy calculations and multiple short molecular dynamics simulations.
    Wang Y; Wu S; Wang L; Yang Z; Zhao J; Zhang L
    RSC Adv; 2020 Dec; 11(2):745-759. PubMed ID: 35423696
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of a Bromodomain and Extra Terminal Domain (BET) Inhibitor with the Selectivity for the Second Bromodomain (BD2) and the Capacity for the Treatment of Inflammatory Diseases.
    Wang Z; Yin L; Xiong Z; Huang F; Yang N; Jiang F; Li H; Cui Y; Ren J; Cheng Z; Jia K; Lu T; Zhu J; Hu Q; Chen Y
    J Med Chem; 2023 Aug; 66(15):10824-10848. PubMed ID: 37478496
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of a brain-permeable bromodomain and extra terminal domain (BET) inhibitor with selectivity for BD1 for the treatment of multiple sclerosis.
    Chen X; Wu T; Du Z; Kang W; Xu R; Meng F; Liu C; Chen Y; Bao Q; Shen J; You Q; Cao D; Jiang Z; Guo X
    Eur J Med Chem; 2024 Feb; 265():116080. PubMed ID: 38142510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DW71177: A novel [1,2,4]triazolo[4,3-a]quinoxaline-based potent and BD1-Selective BET inhibitor for the treatment of acute myeloid leukemia.
    Ali I; Cha HJ; Lim B; Chae CH; Youm J; Park WJ; Lee SH; Kim JH; Jeong D; Lim JK; Hwang YH; Roe JS; Woo JS; Lee K; Choi G
    Eur J Med Chem; 2024 Feb; 265():116052. PubMed ID: 38134745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Domain-Selective BET Ligands Yield Next-Generation Synthetic Genome Readers/Regulators with Nonidentical Cellular Functions.
    Mohammed A; Waddell MB; Sutkeviciute I; Danda A; Philips SJ; Lang W; Slavish PJ; Kietlinska SJ; Kaulage M; Sourav D; Ansari AZ
    J Am Chem Soc; 2023 Nov; ():. PubMed ID: 37923569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Binding pocket-based design, synthesis and biological evaluation of novel selective BRD4-BD1 inhibitors.
    Ma J; Chen H; Yang J; Yu Z; Huang P; Yang H; Zheng B; Liu R; Li Q; Hu G; Chen Z
    Bioorg Med Chem; 2019 May; 27(9):1871-1881. PubMed ID: 30926312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structure-Guided Design of a Domain-Selective Bromodomain and Extra Terminal N-Terminal Bromodomain Chemical Probe.
    Bradley E; Fusani L; Chung CW; Craggs PD; Demont EH; Humphreys PG; Mitchell DJ; Phillipou A; Rioja I; Shah RR; Wellaway CR; Prinjha RK; Palmer DS; Kerr WJ; Reid M; Wall ID; Cookson R
    J Med Chem; 2023 Dec; 66(23):15728-15749. PubMed ID: 37967462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and Evaluation of [
    Wang Y; Wang Y; Xu Y; Tocci D; Wang C
    ACS Omega; 2024 Aug; 9(34):36177-36184. PubMed ID: 39220497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of a potent orally available pyrazolopyridone derivative as a novel selective bromodomain and extra-terminal domain (BET)-first bromodomain (BD1) inhibitor.
    Hagihara S; Ishizawa K; Soga K; Honjo T; Takai S; Kawano Y; Kikuchi M; Nishidate A; Matsumoto F; Murase M; Hashimoto N; Sasaki C; Miyaguchi I; Okada O; Akashi T; Nakayama S; Ogasawara Y; Endo J
    Bioorg Med Chem Lett; 2024 Sep; 109():129849. PubMed ID: 38876177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of the natural product 3',4',7,8-tetrahydroxyflavone as a novel and potent selective BRD4 bromodomain 2 inhibitor.
    Li J; Zou W; Yu K; Liu B; Liang W; Wang L; Lu Y; Jiang Z; Wang A; Zhu J
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):903-913. PubMed ID: 33820450
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune Disease.
    Jahagirdar R; Attwell S; Marusic S; Bendele A; Shenoy N; McLure KG; Gilham D; Norek K; Hansen HC; Yu R; Tobin J; Wagner GS; Young PR; Wong NCW; Kulikowski E
    Mol Pharmacol; 2017 Dec; 92(6):694-706. PubMed ID: 28974538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A "Goldilocks Zone" for Recruiting BET Proteins with Bromodomain-1-Selective Ligands.
    Mohammed A; Churion K; Danda A; Philips SJ; Ansari AZ
    ACS Chem Biol; 2024 Oct; ():. PubMed ID: 39401417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Classical molecular dynamics and metadynamics simulations decipher the mechanism of CBP30 selectively inhibiting CBP/p300 bromodomains.
    Wang Q; An X; Xu J; Wang Y; Liu L; Leung EL; Yao X
    Org Biomol Chem; 2018 Sep; 16(35):6521-6530. PubMed ID: 30160288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonequivalent response to bromodomain-targeting BET inhibitors in oligodendrocyte cell fate decision.
    Chiang CM
    Chem Biol; 2014 Jul; 21(7):804-6. PubMed ID: 25036774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of a potent, orally available furopyridine derivative as a novel selective bromodomain and extra-terminal domain (BET)-first bromodomain (BD1) inhibitor.
    Hagihara S; Ishizawa K; Kikuchi M; Kawano Y; Nishidate A; Matsumoto F; Hashimoto N; Sasaki C; Miyaguchi I; Okada O; Akashi T; Nakayama S; Ogasawara Y; Endo J
    Bioorg Med Chem Lett; 2024 Sep; 109():129848. PubMed ID: 38876176
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.
    Wellaway CR; Bamborough P; Bernard SG; Chung CW; Craggs PD; Cutler L; Demont EH; Evans JP; Gordon L; Karamshi B; Lewis AJ; Lindon MJ; Mitchell DJ; Rioja I; Soden PE; Taylor S; Watson RJ; Willis R; Woolven JM; Wyspiańska BS; Kerr WJ; Prinjha RK
    J Med Chem; 2020 Sep; 63(17):9020-9044. PubMed ID: 32787145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of a Series of
    Harrison LA; Atkinson SJ; Bassil A; Chung CW; Grandi P; Gray JRJ; Levernier E; Lewis A; Lugo D; Messenger C; Michon AM; Mitchell DJ; Preston A; Prinjha RK; Rioja I; Seal JT; Taylor S; Wall ID; Watson RJ; Woolven JM; Demont EH
    J Med Chem; 2021 Aug; 64(15):10742-10771. PubMed ID: 34232650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of a Highly Selective BET BD2 Inhibitor from a DNA-Encoded Library Technology Screening Hit.
    Rianjongdee F; Atkinson SJ; Chung CW; Grandi P; Gray JRJ; Kaushansky LJ; Medeiros P; Messenger C; Phillipou A; Preston A; Prinjha RK; Rioja I; Satz AL; Taylor S; Wall ID; Watson RJ; Yao G; Demont EH
    J Med Chem; 2021 Aug; 64(15):10806-10833. PubMed ID: 34251219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure-Based Discovery and Optimization of Furo[3,2-
    Li J; Zhang C; Xu H; Wang C; Dong R; Shen H; Zhuang X; Chen X; Li Q; Lu J; Zhang M; Wu X; Loomes KM; Zhou Y; Zhang Y; Liu J; Xu Y
    J Med Chem; 2022 Apr; 65(7):5760-5799. PubMed ID: 35333526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.